
Maud Maho-Vaillant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9202389/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab. Frontiers in Immunology, 2022, 13, 849790.	4.8	1
2	FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Frontiers in Immunology, 2022, 13, .	4.8	9
3	Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus. Journal of Investigative Dermatology, 2021, 141, 2132-2140.e1.	0.7	13
4	Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment. Biomedicines, 2021, 9, 1411.	3.2	1
5	Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen. Frontiers in Immunology, 2019, 10, 1794.	4.8	20
6	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet, The, 2017, 389, 2031-2040.	13.7	438
7	Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response. Science Translational Medicine, 2013, 5, 175ra30.	12.4	200